The Biostatistics Core will play a pivotal role in the Northwest Prostate Cancer SPORE, interacting with virtually every project and Core. The defining goal of the Biostatistics Core will be to assist investigators in formulating studies that can feasibly address the questions of scientific interest, are amenable to statistical analysis, and will ultimately yield statistically valid and interpretable results. This Core will link study design, data collection, measurement, and analysis to the critical hypotheses and questions of the Northwest Prostate Cancer SPORE through the following Specific Aims: 1. Design: Define study hypotheses, study populations and experimental parameters to answer the research questions of interest, reduce systematic bias and ensure a high likelihood of detection of biologically meaningful effects. 2. Analysis: Identify and implement quantitative methods to address the scientific questions of interest and provide valid statistical inferences about the evidence supporting the various study hypotheses. To implement analyses of genomic expression data, the Biostatistics Core will utilize a software system for analysis of genomic expression data, currently under development at the Fred Hutchinson Cancer Research Center. This system will provide researchers on the SPORE with a user-friendly interface to a variety of standard as well as novel computational algorithms for the analysis of expression data. The Biostatistics Core will work closely with the Informatics and Gene Expression Core to define the microarray database for the array expression data generated by the proposed SPORE, and to select procedures for data normalization and quality control. The Biostatistics Core will also work with the Clinical Research Core to define the structure of a new clinical database, to design clinical trials of new treatment strategies and to design clinical validation studies for confirming the importance of genes discovered through SPORE projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA097186-01
Application #
6671831
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-19
Project End
2007-04-30
Budget Start
Budget End
Support Year
1
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Plymate, Stephen R; Sharp, Adam; de Bono, Johann S (2018) Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail. JAMA Oncol 4:1187-1188
Russo, Joshua W; Gao, Ce; Bhasin, Swati S et al. (2018) Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res 78:6354-6362
Sowalsky, Adam G; Ye, Huihui; Bhasin, Manoj et al. (2018) Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res 78:4716-4730
Zhu, Yezi; Sharp, Adam; Anderson, Courtney M et al. (2018) Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol 73:727-735
Chalfin, Heather J; Glavaris, Stephanie A; Malihi, Paymaneh D et al. (2018) Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. J Urol 199:1494-1501
Inoue, Lurdes Y T; Lin, Daniel W; Newcomb, Lisa F et al. (2018) Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Ann Intern Med 168:1-9
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Levesque, Christine; Nelson, Peter S (2018) Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance. Cold Spring Harb Perspect Med 8:
Barnard, Monique; Quanson, Jonathan L; Mostaghel, Elahe et al. (2018) 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer. J Steroid Biochem Mol Biol 183:192-201
Ganaie, Arsheed A; Beigh, Firdous H; Astone, Matteo et al. (2018) BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models. Clin Cancer Res 24:6421-6432

Showing the most recent 10 out of 400 publications